Hematology

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

Review top news and interview highlights from the week ending December 5, 2025.

The agency's decision was based on results from an r/r MZL cohort in the phase 2 TRANSCEND FL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed lessons that should guide the next generation of developers and regulators entering the field.

In episode 7 of ImmunoLogic, Anusha Kalbasi, MD, discussed his research on the use of IL-9 to enhance CAR-T efficacy.

Review top news and interview highlights from the week ending November 28, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about streamlining collaboration to speed up advancement of new therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending November 21, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about strategies for streamlining development of novel therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chair of the Division of Hematology at Mayo Clinic discussed practical considerations for the introduction of cell therapies for the treatment of hematologic malignancies.

Review top news and interview highlights from the week ending November 7, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed major events in the past quarter century of cell and gene therapy research.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed how AI will affect cell and gene therapy research and practice.

Review top news and interview highlights from the week ending October 31, 2025.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on reducing costs for cell and gene therapy products.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on the future of cell and gene therapy.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, about the importance of big wins for cell and gene therapy research.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared advice for young scientists entering the cell and gene therapy field.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the unpredictability of "living drugs" in the human body and the ongoing development of understanding.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on how streamlined collaboration can help move therapies to patients faster.